U.S. Markets closed

Viatris Inc. (VTRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.57-0.12 (-0.88%)
At close: 4:00PM EDT

Viatris Inc.

1000 Mylan Boulevard
Canonsburg, PA 15317
United States
724 514 1800
http://www.viatris.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees40,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert J. CouryExec. Chairman16.61MN/A1961
Mr. Michael GoettlerCEO & Exec. Director3.07MN/A1968
Mr. Rajiv MalikPres & Exec. Director6.87MN/A1961
Mr. Sanjeev NarulaChief Financial Officer2.5MN/A1961
Mr. Anthony MauroPres of Developed Markets3.54MN/A1973
Mr. Sanjeev Kumar SethiChief Operating OfficerN/AN/A1967
Mr. Paul B. CampbellChief Accounting Officer, Sr. VP & Corp. ControllerN/AN/A1967
Mr. Ramkumar RayapureddyChief Information OfficerN/AN/AN/A
Ms. Melissa TrombettaHead of Global Investor RelationsN/AN/AN/A
Mr. Brian S. RomanGlobal Gen. CounselN/AN/A1970
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.

Corporate Governance

Viatris Inc.’s ISS Governance QualityScore as of July 1, 2021 is 9. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.